JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Acute dorsal trans-scaphoid perilunate fracture-dislocations: medium-term results.

The purpose of this study was to investigate the medium-term results (mean follow-up, 8 years) of a series of 14 trans-scaphoid dorsal perilunate fracture-dislocations treated operatively at an average of 6 days following injury. Eleven underwent open reduction and internal fixation through a dorsal approach. Combined palmar and dorsal approaches were used in only three cases, for open reduction and internal fixation in two and proximal row carpectomy in one. The Mayo wrist score revealed five excellent, three good, five fair and one poor result. The average score was 79% (range 55-95%). All internally fixed scaphoids healed and no lunate or scaphoid fragment avascular necrosis with collapse was observed. Carpal alignment was satisfactory in most cases. Post-traumatic radiological midcarpal and/or radiocarpal arthritis were almost always observed at follow-up, but this did not correlate with the Mayo wrist score.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app